NewEdge Advisors’s VanEck Biotech ETF BBH Stock Holding History

NewEdge Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.92K	Sell	37 -2	-5%	-$385	﹤0.01%	3489
2025 Q4	$7.34K	Hold	39	–	–	﹤0.01%	3564
2025 Q3	$6.39K	Hold	39	–	–	﹤0.01%	3459
2025 Q2	$5.92K	Hold	39	–	–	﹤0.01%	3367
2025 Q1	$6.07K	Hold	39	–	–	﹤0.01%	3247
2024 Q4	$6.06K	Buy	39 +1	+3%	+$168	﹤0.01%	3179
2024 Q3	$6.8K	Hold	38	–	–	﹤0.01%	3061
2024 Q2	$6.45K	Hold	38	–	–	﹤0.01%	3006
2024 Q1	$6.37K	Hold	38	–	–	﹤0.01%	3051
2023 Q4	$6.33K	Sell	38 -20	-34%	-$3.08K	﹤0.01%	3038
2023 Q3	$9.07K	Hold	58	–	–	﹤0.01%	2600
2023 Q2	$9.09K	Hold	58	–	–	﹤0.01%	2628
2023 Q1	$9.44K	Buy	58 +13	+29%	+$2.1K	﹤0.01%	2585
2022 Q4	$7	Buy	+45	New	+$7.13K	﹤0.01%	3749

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

NewEdge Advisors's BBH Position: Q1 2026 in Review

NewEdge Advisors reduced its VanEck Biotech ETF (BBH) stake by 5.1% in Q1 2026, selling an estimated $385 and leaving 37 shares worth $6.92K. The position accounts for ﹤0.01% of the portfolio, ranked #3489.

NewEdge Advisors first reported a position in BBH in Q4 2022 and has held it in 14 quarters since. The position peaked at $9.44K in Q1 2023. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

NewEdge Advisors held 37 shares of VanEck Biotech ETF worth $6.92K as of Q1 2026.
NewEdge Advisors sold 2 VanEck Biotech ETF shares in Q1 2026, an estimated $385.
VanEck Biotech ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3489 holding.
NewEdge Advisors first reported a position in VanEck Biotech ETF in Q4 2022 and has held it in 14 quarters since.
NewEdge Advisors's VanEck Biotech ETF position peaked at $9.44K in Q1 2023.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.